The legal status of research peptides in the US is a common source of confusion. Here is a clear, factual breakdown of where things stand in 2026.
The question of legality around research peptides comes up constantly — and for good reason. The regulatory landscape is genuinely complex, and misleading information from both overly cautious and overly permissive sources doesn't help. Here is a clear, factual breakdown.
The United States does not have a single, comprehensive law that governs all peptides. Instead, the regulatory framework depends on how the compound is sold and what claims are made about it.
The key principle: Compounds sold explicitly "for research use only" — with no claims of human therapeutic use, no human consumption instructions, and no marketing as drugs or dietary supplements — occupy a distinct legal space. They are not approved drugs (which would require FDA New Drug Approval), but they are also not necessarily unapproved drugs if they are not being sold as such.
The FDA's jurisdiction over a substance is largely triggered by the *intended use* as represented by the seller. A compound sold with legitimate research-use labeling, no therapeutic claims, and no human-dosing instructions is treated differently from the same compound sold as a treatment or supplement.
Most research peptides — including TB-500, BPC-157, CJC-1295, Ipamorelin, GHK-Cu, Epitalon, Semax, KPV, MOTS-C, and DSIP — are not scheduled substances under the Controlled Substances Act. They are not DEA-controlled compounds, which means their purchase, possession, and use in legitimate research contexts does not carry the criminal liability associated with Schedule I–V substances.
Retatrutide and similar GLP-1 class compounds exist in a more carefully watched regulatory space, as the FDA has taken active interest in GLP-1 analogues given their therapeutic market. Researchers should stay current with FDA guidance specific to any GLP-1 analogue they are working with.
Credible research peptide suppliers like Corevanta: - Sell compounds with explicit "for research purposes only" labeling - Make no human therapeutic claims on product pages or marketing materials - Require customers to acknowledge the research-use designation - Provide third-party Certificates of Analysis for every batch - Do not provide medical advice or dosing guidance for human use
These practices keep suppliers and their customers within the appropriate legal framework for research-use compounds.
While federal law is the primary framework, some states have additional regulations around specific compounds or compound classes. Researchers should review applicable state regulations for their jurisdiction, particularly in states that have enacted broader regulatory frameworks around peptides or peptide derivatives.
Research peptides sold by reputable suppliers with proper research-use designation, transparent COA documentation, and no therapeutic claims are operated within a legally defensible framework under current US law. They are not approved drugs, not scheduled substances (for most compounds), and not dietary supplements — they occupy the research-use regulatory category.
For any specific legal question about a particular compound or research context, consultation with a regulatory attorney familiar with FDA law is advisable.
*Corevanta sells all peptides for research purposes only. Nothing on this site constitutes legal or medical advice.*
Research compounds discussed in this article
All compounds discussed in this article are sold by Corevanta for laboratory research purposes only. They are not approved drugs, not dietary supplements, and are not intended for human consumption or therapeutic use. Always comply with applicable local regulations.